Table 1.
Clinical features and autoantibodies in SLE patients with and without demyelinating syndromes.
| Clinical manifestations | SLE with demyelination (n = 26) | SLE (n = 681) | P-value |
|---|---|---|---|
| Acute cutaneous lupus, n (%) | 24(92.3) | 487(71.5) | 0.02 |
| Malar rash, n (%) | 17(65.4) | 325(47.7) | 0.08 |
| Photosensitivity, n (%) | 8(30.8) | 381(55.9) | 0.01 |
| Chronic cutaneous lupus n (%) | 2(7.7) | 76(11.2) | ns |
| Oral ulcers, n (%) | 6(23) | 189(27.8) | ns |
| Non-scarring alopecia, n (%) | 6(23) | 236(34.7) | ns |
| Inflammatory arthritis, n (%) | 24(92.3) | 581(85.3) | ns |
| Serositis, n (%) | 2(7.7) | 128(18.8) | 0.15 |
| Lupus nephritis, n (%) | 1(3.8) | 149(21.9) | 0.03 |
| Neuropsychiatric events*, n (%) | 6(23) | 109(16) | ns |
| Leukopenia, n (%) | 4(15.4) | 240(35.2) | 0.04 |
| Thrombocytopenia, n (%) | 0(0) | 116(17) | ns |
| Hemolytic anemia, n (%) | 0(0) | 24(3.5) | ns |
| Fever, n (%) | 2(7.7) | 223(33.6) | 0.007 |
| Raynaud's, n (%) | 8(30.8) | 260(38.2) | ns |
| Autoantibodies | |||
| ANA, n (%) | 24(92.3) | 658(96.6) | ns |
| Anti-dsDNA, n (%) | 7(26.9) | 285(41.6) | ns |
| Anti-Smith, n (%) | 2(7.7) | 52(7.6) | ns |
| Low C3 and/or C4, n (%) | 12(46.2) | 329(48.3) | ns |
| Anti-SSA, n (%) | 7(26.9) | 180(26.4) | ns |
| Anti-SSB, n (%) | 3(11.5) | 72(10.6) | ns |
| Anti-phospholipids, n (%) | 3(11.5) | 181(26.6) | 0.08 |
| Anti-RNP, n (%) | 3(11.5) | 60(8.8) | ns |
*
Excluding demyelinating events. Values in bold represent comparisons that reached statistical significance (P < 0.05).